Announcement of the U.S. FDA approval on Orphan Drug Designation of Globo H antibody drug conjugate, OBI-999, targeting Pancreatic Cancer

Date of occurrence of the event: Dec 24, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not applicable Cause of occurrence: OBI received the letter of notification from the U.S. FDA about the approval on qualifying Globo H antibody-drug conjugate, OBI-999, for […]

This article is password protected.

To view the content, please enter your password in the field below